- Home
- MNPR vs INBX Comparison
MNPR vs INBX Comparison
Compare MNPR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- INBX
- Stock Information
- Founded
- MNPR 2014
- INBX 2010
- Country
- MNPR United States
- INBX United States
- Employees
- MNPR N/A
- INBX N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- MNPR Health Care
- INBX Health Care
- Exchange
- MNPR Nasdaq
- INBX Nasdaq
- Market Cap
- MNPR 390.5M
- INBX 430.2M
- IPO Year
- MNPR 2019
- INBX 2020
- Fundamental
- Price
- MNPR $99.37
- INBX $33.88
- Analyst Decision
- MNPR Strong Buy
- INBX Hold
- Analyst Count
- MNPR 12
- INBX 2
- Target Price
- MNPR $89.82
- INBX N/A
- AVG Volume (30 Days)
- MNPR 78.9K
- INBX 123.8K
- Earning Date
- MNPR 11-07-2025
- INBX 11-13-2025
- Dividend Yield
- MNPR N/A
- INBX N/A
- EPS Growth
- MNPR N/A
- INBX N/A
- EPS
- MNPR N/A
- INBX N/A
- Revenue
- MNPR N/A
- INBX $1,400,000.00
- Revenue This Year
- MNPR N/A
- INBX $563.00
- Revenue Next Year
- MNPR N/A
- INBX $230.77
- P/E Ratio
- MNPR N/A
- INBX N/A
- Revenue Growth
- MNPR N/A
- INBX N/A
- 52 Week Low
- MNPR $4.50
- INBX $10.81
- 52 Week High
- MNPR $105.00
- INBX $37.53
- Technical
- Relative Strength Index (RSI)
- MNPR 88.79
- INBX 70.48
- Support Level
- MNPR $72.41
- INBX $31.75
- Resistance Level
- MNPR $105.00
- INBX $37.53
- Average True Range (ATR)
- MNPR 7.21
- INBX 1.99
- MACD
- MNPR 2.86
- INBX 0.27
- Stochastic Oscillator
- MNPR 89.52
- INBX 67.77
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.